Recent studies have reported that the timing of PD-1 inhibition could negatively affect T-cell priming and memory CD8+ T cell formation, thus contributing to more appropriate timings in RCC immunotherapy [16, 17]. Here, CD8A is linked to renal cell carcinoma.